Free Trial
NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

MiNK Therapeutics logo
$7.55 +0.15 (+2.04%)
As of 02:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MiNK Therapeutics Stock (NASDAQ:INKT)

Key Stats

Today's Range
$7.70
$7.70
50-Day Range
$7.26
$9.73
52-Week Range
$4.56
$13.79
Volume
794 shs
Average Volume
14,473 shs
Market Capitalization
$29.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50
Consensus Rating
Buy

Company Overview

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

MiNK Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

INKT MarketRank™: 

MiNK Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 465th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MiNK Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MiNK Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about MiNK Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MiNK Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MiNK Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MiNK Therapeutics is -1.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about MiNK Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.65% of the float of MiNK Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MiNK Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MiNK Therapeutics has recently increased by 10.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MiNK Therapeutics does not currently pay a dividend.

  • Dividend Growth

    MiNK Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.65% of the float of MiNK Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MiNK Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MiNK Therapeutics has recently increased by 10.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MiNK Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.60% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.87% of the stock of MiNK Therapeutics is held by institutions.

  • Read more about MiNK Therapeutics' insider trading history.
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INKT Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
MiNK Therapeutics reports Q4 EPS (62c), consensus (50c)
Q4 2024 Mink Therapeutics Inc Earnings Call
See More Headlines

INKT Stock Analysis - Frequently Asked Questions

MiNK Therapeutics' stock was trading at $6.9690 at the beginning of 2025. Since then, INKT stock has increased by 8.4% and is now trading at $7.5510.
View the best growth stocks for 2025 here
.

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its quarterly earnings results on Tuesday, March, 18th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.12.
Read the conference call transcript
.

Shares of MiNK Therapeutics reverse split before market open on Tuesday, January 28th 2025. The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC).

Company Calendar

Last Earnings
3/18/2025
Today
5/02/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INKT
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.50
High Stock Price Target
$40.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+396.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($5.23) per share
Price / Book
-1.44

Miscellaneous

Free Float
3,147,000
Market Cap
$29.95 million
Optionable
No Data
Beta
0.15
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:INKT) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners